On March 5, 2026, the Medicines and Healthcare products Regulatory Agency (MHRA), together with the UK Space Agency, the Regulatory Innovation Office (RIO), and the Civil Aviation Authority (CAA), announced new regulatory guidance for pharmaceuticals manufactured in space.
The initiative outlines how existing UK medicines and spaceflight regulatory frameworks may apply to medicines produced in microgravity environments, particularly biologics and other complex therapies. The guidance aims to support companies developing space-enabled pharmaceutical manufacturing while clarifying regulatory expectations for approval and market access in the United Kingdom.
Details of the Update
The newly introduced guidance explains how existing UK medicines regulations apply to pharmaceuticals manufactured in orbit using microgravity platforms. The framework helps companies understand regulatory expectations for product development, manufacturing standards, and eventual market authorization.
In addition, regulators will introduce a Re-entry Regulatory Sandbox, designed to support companies testing regulatory approaches for safely returning space-manufactured products to Earth. This sandbox environment allows regulators and industry stakeholders to evaluate operational, safety, and compliance considerations related to re-entry and product handling.
To further support industry understanding, the agencies will publish principles-based case studies demonstrating potential regulatory pathways for space-enabled pharmaceutical manufacturing. These examples are intended to help organizations evaluate how existing regulations could apply to different manufacturing scenarios in microgravity environments.
The initiative also emphasizes early engagement with MHRA’s scientific and regulatory advice services, encouraging companies to consult regulators during development planning to better understand applicable regulatory requirements.
Finally, the program highlights the importance of strengthening collaboration across the pharmaceutical and space technology supply chain, helping facilitate the long-term commercialization of space-manufactured medicines.
Why It Matters
This regulatory initiative provides greater clarity on how existing UK medicines and spaceflight regulations apply to pharmaceuticals produced in microgravity environments. By establishing guidance, case studies, and a regulatory sandbox, the framework supports innovation while maintaining regulatory oversight. It also promotes regulatory alignment, improved development planning, and efficient pathways for emerging space-enabled life sciences technologies.
Who This Is Relevant For
The guidance is particularly relevant for pharmaceutical manufacturers, biotechnology companies, and microgravity platform providers exploring the development of biologics, advanced therapies, and other complex medicines that may benefit from microgravity manufacturing environments.
Next Steps
Organizations involved in space-enabled pharmaceutical manufacturing should review the outlined regulatory approaches and assess whether current or planned initiatives align with the new framework.
Companies developing such technologies are encouraged to engage early with MHRA’s scientific and regulatory advice services to better understand applicable regulatory pathways, development considerations, and compliance requirements.
As regulatory frameworks evolve to support emerging technologies such as space-based manufacturing, regulatory teams must stay ahead of new guidance and cross-sector policy developments. RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, streamlining compliance processes, mitigating risks, and accelerating market access across more than 160 countries. Learn more or book a demo now.
FAQs
What is the MHRA guidance on space-manufactured medicines?
The guidance clarifies how existing UK medicines and spaceflight regulatory frameworks apply to pharmaceuticals produced in microgravity environments, including development, regulatory engagement, and product return to Earth.
What is the Re-entry Regulatory Sandbox?
The Re-entry Regulatory Sandbox is a regulatory testing environment designed to help companies evaluate approaches for safely returning space-manufactured pharmaceutical products from orbit to Earth.
Which types of medicines are most relevant to microgravity manufacturing?
The initiative highlights biologics, advanced therapies, and other complex medicines as areas that may benefit from manufacturing processes conducted in microgravity environments.
How can RegASK help companies monitor regulatory updates related to infant formulas?
RegASK helps regulatory and compliance teams monitor evolving global regulations, assess regulatory impact, and manage compliance workflows across jurisdictions, enabling organizations to stay informed and prepared as new regulatory pathways for emerging technologies are introduced.
Subscribe to the latest regulatory news
Curated newsletters
Relevant industry info
Access expert insights
